Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,013 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: social interaction Clear all
Terminated Not applicable Interventional

Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial

NCT02024685
View directory record Official record
Conditions
Adenocarcinoma of Prostate, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
Interventions
Personalized Treatment Recommendations, Standard patient-physician counseling interaction
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

NCT02807116
View directory record Official record
Conditions
Healthy Subjects
Interventions
Pacritinib, Rifampin, Pacritinib and Rifampin
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Agitation in People With Dementia: the Customized Activity Trial

NCT01892579
View directory record Official record
Conditions
Dementia
Interventions
Tailored Activity Program, Home Safety and Education Program
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Individualized Assessment and Treatment for Alcoholism II

NCT03233802
View directory record Official record
Conditions
Alcoholism
Interventions
Individualized Assess & Treatment (IATP), Packaged Cognitive-Behavioral (PCBT), Case Management (CaseM)
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 18, 2026, 7:16 AM EDT
Not listed No phase listed Observational

Caring for the Whole Person

NCT03034369
View directory record Official record
Conditions
Behavioral Health
Interventions
Access to Care, Depression Screening, Patient-Provider Relationship, Patient-Clinic Interactions, Stigma, Provider Continuity, Symptom Severity, Diagnoses, Social support, Preventive Screening, Inpatient Hospitalization Utilization, Inpatient Readmissions, Post-Admission follow-up
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Not applicable Interventional Results available

Contingency Management for Smoking in Substance Abusers

NCT00807742
View directory record Official record
Conditions
Substance Abuse
Interventions
Nicotine Replacement Treatment (NRT), Brief Advice, Contingency Management, Non-Contingent Reinforcement
Drug · Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 18, 2026, 7:16 AM EDT
Recruiting Phase 2 Interventional

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

NCT06954805
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell
Interventions
Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq
Drug · Device
Lead sponsor
Jennifer Amengual
Other
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 18, 2026, 7:16 AM EDT
Completed No phase listed Observational

The Relationship Between Positive End Expiratory Pressure and Cardiac Index in Patients With Acute Respiratory Distress Syndrome (ARDS) Managed on a Fluid Protocol

NCT01714583
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response

NCT03694119
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Phenelzine, Tyramine, Phenelzine placebo, ozanimod placebo, ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
25 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

NCT04530981
View directory record Official record
Conditions
GIST - Gastrointestinal Stromal Tumor
Interventions
Ripretinib, Repaglinide
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • Miami, Florida • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Sequenced Behavioral and Medication Intervention for Cocaine Dependence

NCT01986075
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Computer-assisted behavior therapy, Mixed-Amphetamine Salts- Extended Release (MAS-ER), Placebo
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers

NCT01364987
View directory record Official record
Conditions
Healthy Subjects, Drug Interactions, Pharmacokinetics of ASP015K
Interventions
ASP015K, Mycophenolate Mofetil
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2011 · Synced Oct 18, 2026, 7:16 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity.

NCT06053567
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Aerobic Exercise, Counseling, Nicotine patch
Behavioral · Drug
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 18, 2026, 7:16 AM EDT
Terminated Phase 1 Interventional

Study of Pomaglumetad and Methamphetamine

NCT03106571
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Pomaglumetad methionil, Placebo, Methamphetamine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 18, 2026, 7:16 AM EDT
Terminated Phase 1 Interventional

Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

NCT00288444
View directory record Official record
Conditions
Lung Cancer, Soft Tissue Sarcoma, Colorectal Carcinoma, Breast Cancer, Prostate Cancer
Interventions
Lonafarnib, Docetaxel
Drug
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 18, 2026, 7:16 AM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation

NCT05112432
View directory record Official record
Conditions
Psychosis
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Duluth, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 18, 2026, 7:16 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Pilot Study of Teacher-Child Interaction Training - Universal in Head Start

NCT04075071
View directory record Official record
Conditions
Child Behavior, Child Development, Child Behavior Problem
Interventions
Teacher-Child Interaction Training - Universal
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 18, 2026, 7:16 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Investigation of Mechanisms of Action in Superpower Glass

NCT04049981
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism
Interventions
Superpower Glass
Device
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 8 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 18, 2026, 7:16 AM EDT
Terminated Not applicable Interventional

Sibling-Mediated Intervention on Literacy and Reciprocity for Children With Autism

NCT05098392
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Sibling-mediated intervention
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
5 Years to 11 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Round Rock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

NCT03723395
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
tucatinib, itraconazole, rifampin, gemfibrozil, repaglinide, tolbutamide, midazolam, digoxin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing Teen Pregnancy in the Emergency Department

NCT03866811
View directory record Official record
Conditions
Reproductive Behavior, Sexual Behavior, Adolescent Behavior, Contraception
Interventions
Dr. Erica
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
14 Years to 19 Years · Female only
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 18, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects

NCT04783753
View directory record Official record
Conditions
Hepatitis B
Interventions
EDP-514, Itraconazole, Carbamazepin, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 18, 2026, 7:16 AM EDT
Not yet recruiting Phase 2 Interventional

The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

NCT07146230
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab, Monalizumab, Oleclumab, Radiotherapy
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 18, 2026, 7:16 AM EDT